Sign In
Buy KMDA
$7.39
-0.120 (-1.60%)
At Close: Jun 03, 2026
Kamada (KMDA) Receives a Buy from Chardan Capital
01:30pm, Thursday, 13'th Feb 2020
In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Kamada (KMDA – Research Report),
Kamada Reports Financial Results for Fourth Quarter and Fiscal Year 2019
12:00pm, Wednesday, 12'th Feb 2020
Total Revenues for Fiscal 2019 were $127.2 million, up 11% as Compared to 2018Gross Profit for Fiscal 2019 was $49.7 Million, up 20% as Compared to 2018Adjusted EBITDA for.
Kamada Q4 EPS $0.13, Inline, Sales $32.071M Miss $33.04M Estimate
12:00am, Wednesday, 12'th Feb 2020Research Analysts' Upgrades for February, 7th (ALNY, AMAT, ASTE, AUPH, AVAV, BJRI, CDNA, CLVS, CYTK, EBIX)
09:28am, Friday, 07'th Feb 2020
Research Analysts’ upgrades for Friday, February 7th: Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by analysts at BidaskClub from a buy rating to a strong-buy rating. Applied Materials (NASDAQ
Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2019 Financial Results and Host Conference Call on February 12, 2020
12:00pm, Wednesday, 05'th Feb 2020
Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2019,
Kamada to Announce Fourth Quarter and Fiscal Year Ended December '–, —…–9 Financial ...
12:00am, Wednesday, 05'th Feb 2020Kamada Announces $25 Million Private Placement with FIMI Opportunity Fund
12:00pm, Tuesday, 21'st Jan 2020
Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that it has entered into a securities purchase agreement with FIMI Opportunity Funds (FIMI), the lea
Kamada Announces $25M Private Placement With FIMI Opportunity Fund; Co. To Issue ~4.17M Shares To FIMI At $6/Share
12:00am, Tuesday, 21'st Jan 2020Why Kamada (KMDA) Could Beat Earnings Estimates Again
05:10pm, Friday, 17'th Jan 2020
Kamada (KMDA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2019 and Provides Full-Year 2020 Revenue Guidance
12:00pm, Tuesday, 07'th Jan 2020
Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today preliminary and unaudited total revenue for the fourth quarter and full-year 2019. Total revenue for
Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that the first patient has been randomized in Europe into its pivotal Phase 3 InnovAATe clinical trial
Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics company, today announced that it has entered into a binding term sheet for a 12-year contract manufacturing agreement w
